The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) requests $180,000 per year in developmental funds, 17% of the overall direct Cancer Center Support Grant (CCSG) request, that will be used specifically to: ? Provide pilot research funding to HCC members annually, a total of $80,000 per year, to promote translational research in high priority areas as articulated by the HCC leadership. ? Provide funding, $100,000 per year, for start-up packages for high priority new faculty recruitment. These CCSG Developmental Funds will be employed to directly fulfill key components of the HCC's strategic research plans for 2014-2018.

Public Health Relevance

The Hollings Cancer Center (HCC) requests Developmental Funds from the Cancer Center Support Grant to fund pilot research projects and recruit new faculty to MUSC. Both endeavors will support the overall mission of the HCC, which is to reduce the cancer burden in South Carolina and beyond.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA138313-06
Application #
8695839
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-04-01
Project End
2019-03-31
Budget Start
2014-06-20
Budget End
2015-03-31
Support Year
6
Fiscal Year
2014
Total Cost
$233,115
Indirect Cost
$76,422
Name
Medical University of South Carolina
Department
Type
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29403
Song, J H; An, N; Chatterjee, S et al. (2015) Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-induced cell killing. Oncogene 34:3728-36
Zemskova, Marina Y; Song, Jin H; Cen, Bo et al. (2015) Regulation of prostate stromal fibroblasts by the PIM1 protein kinase. Cell Signal 27:135-46
Boppana, Nithin B; Kodiha, Mohamed; Stochaj, Ursula et al. (2014) Ceramide synthase inhibitor fumonisin B1 inhibits apoptotic cell death in SCC17B human head and neck squamous carcinoma cells after Pc4 photosensitization. Photochem Photobiol Sci 13:1621-7
God, Jason M; Zhao, Dan; Cameron, Christine A et al. (2014) Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition. Immunology 142:492-505
Esnaola, Nestor F; Chaudhary, Uzair B; O'Brien, Paul et al. (2014) Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 88:837-44
Fuseler, John W; Robichaux, Jacqulyne P; Atiyah, Huda I et al. (2014) Morphometric and fractal dimension analysis identifies early neoplastic changes in mammary epithelium of MMTV-cNeu mice. Anticancer Res 34:1171-7
Hussey, Sophie E; Lum, Helen; Alvarez, Andrea et al. (2014) A sustained increase in plasma NEFA upregulates the Toll-like receptor network in human muscle. Diabetologia 57:582-91
Chen, Weiqin; Zhou, Hongyi; Saha, Pradip et al. (2014) Molecular mechanisms underlying fasting modulated liver insulin sensitivity and metabolism in male lipodystrophic Bscl2/Seipin-deficient mice. Endocrinology 155:4215-25
Kesarwani, Pravin; Al-Khami, Amir A; Scurti, Gina et al. (2014) Promoting thiol expression increases the durability of antitumor T-cell functions. Cancer Res 74:6036-47
He, Huacheng; Cattran, Alexander W; Nguyen, Tu et al. (2014) Triple-responsive expansile nanogel for tumor and mitochondria targeted photosensitizer delivery. Biomaterials 35:9546-53

Showing the most recent 10 out of 162 publications